The Expert Committee recommended the addition of the fixed-dose combination of sofosbuvir + velpatasvir to the core list of the EMLc for the treatment of children aged 3 to 12 years with chronic HCV infection, based on evidence of pan-genotypic effectiveness and an acceptable safety profile. The Committee noted that the results of the paediatric trial demonstrated high rates of virological response in children and adolescents, comparable with those observed in adults. The Committee therefore also recommended that listing of sofosbuvir + velpatasvir on the EML should be extended to include adolescents. The Committee recognized that in paediatric patients with HCV infection and cirrhosis, co-administration of sofosbuvir + velpatasvir with ribavirin may be required. However, the Committee noted that there was limited evidence on the use of ribavirin in children and the number of children requiring ribavirin co-treatment was very small; therefore, the Committee did not recommend the inclusion of ribavirin on the EMLc. The Committee also noted the planned inclusion of sofosbuvir + velpatasvir as one of the recommended regimens for children in the updated WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection, and the availability of prequalified and generic products in some settings.